Allegan, Michigan based Private Brand manufacturer Perrigo announced that it has initiated market launch and made its first shipments of minoxidil 5% foam to its retail and wholesale customers. Marketed under store or own brands, minoxidil 5% foam is comparable to Rogaine 5% Foam Hair Regrowth Treatment. Rogaine 5% Foam is a treatment for the regrowth of hair on the top of the scalp and its estimated annual sales are approximately $60 million.
On February 10, 2011, Perrigo announced that it successfully settled its Hatch-Waxman litigation relating to minoxidil 5% foam brought by Stiefel Research Australia Pty. Ltd., a GSK Company. As Perrigo was the first party to challenge the brand patent, it is entitled to 180 days of generic marketing exclusivity.
Perrigo’s Chairman and CEO Joseph C. Papa stated, “This is another example of Perrigo’s commitment to launching difficult-to-manufacture pharmaceuticals in topical, lotion and foam delivery systems. We are excited to be the first store brand manufacturer to bring this exclusive product to U.S. consumers. We, and our wholesale and retail customers, are excited about the prospects for this important store brand launch. We continue to be focused upon our company mission of making quality healthcare more affordable to patients and consumers.”